Treatment with rifampicin for Pneumocystis carinii pneumonia. 1984

B Singh, and R S Jones

The role of rifampicin in the treatment of serologically proved Pneumocystis carinii pneumonitis was reported recently from Poland (1). Serum antibody or antigen levels alone provide uncertain evidence as by four years of age two-thirds of normal children may have significant titres (2). We present the first case treated with rifampicin, and proven by open lung biopsy.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D011020 Pneumonia, Pneumocystis A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis. P carinii Pneumonia,P. carinii Pneumonia,P. jirovecii Pneumonia,PCP Pneumonia,Pneumocystis Pneumonia,Pneumocystosis,Pneumonia, Interstitial Plasma Cell,PCP Infection,Pneumocystis carinii Pneumonia,Pneumocystis jirovecii Pneumonia,Pneumonia, Pneumocystis carinii,Infection, PCP,P carinii Pneumonias,P. carinii Pneumonias,P. jirovecii Pneumonias,PCP Infections,PCP Pneumonias,Pneumocystis Pneumonias,Pneumocystoses,Pneumonia, P carinii,Pneumonia, P. carinii,Pneumonia, P. jirovecii,Pneumonia, PCP,Pneumonia, Pneumocystis jirovecii,Pneumonias, PCP
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001706 Biopsy Removal and pathologic examination of specimens from the living body. Biopsies
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin

Related Publications

B Singh, and R S Jones
July 1983, Lancet (London, England),
B Singh, and R S Jones
November 1968, The Medical letter on drugs and therapeutics,
B Singh, and R S Jones
November 1987, The Medical letter on drugs and therapeutics,
B Singh, and R S Jones
November 1987, Parasitology today (Personal ed.),
B Singh, and R S Jones
January 1986, Advances in experimental medicine and biology,
B Singh, and R S Jones
July 1987, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
B Singh, and R S Jones
May 1987, The American journal of medicine,
B Singh, and R S Jones
April 1973, Postgraduate medicine,
B Singh, and R S Jones
June 1964, Canadian Medical Association journal,
B Singh, and R S Jones
November 1976, JAMA,
Copied contents to your clipboard!